Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...

Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo(axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...

Incyte INCY announced new data from a phase I study on pipeline candidate INCB123667 in patients with advanced solid ...

Shares of Incyte Corp. INCY slid 1.90% to $65.17 Wednesday, on what proved to be an all-around grim trading session for the ...

This was the stock's fourth consecutive day of gains.

Incyte (INCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Lebovitz from ...

Incyte Corp (INCY) stock saw a modest uptick, ending the day at $66.82 which represents a slight increase of $1.65 or 2.53% from the prior close of $65.17. The stock opened at $66.22 and touched a low ...

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...

A common immunotherapy approach helped stave off disease progression in patients with a form of anal cancer that is caused by ...

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, ...

JMP Securities analyst Reni Benjamin has maintained their neutral stance on INCY stock, giving a Hold rating yesterday. Reni Benjamin has ...